全文获取类型
收费全文 | 389726篇 |
免费 | 48408篇 |
国内免费 | 3291篇 |
专业分类
耳鼻咽喉 | 7518篇 |
儿科学 | 11637篇 |
妇产科学 | 6857篇 |
基础医学 | 35837篇 |
口腔科学 | 5971篇 |
临床医学 | 50297篇 |
内科学 | 96870篇 |
皮肤病学 | 10555篇 |
神经病学 | 37886篇 |
特种医学 | 14322篇 |
外国民族医学 | 11篇 |
外科学 | 76458篇 |
综合类 | 3675篇 |
现状与发展 | 72篇 |
一般理论 | 318篇 |
预防医学 | 27801篇 |
眼科学 | 9699篇 |
药学 | 17736篇 |
6篇 | |
中国医学 | 367篇 |
肿瘤学 | 27532篇 |
出版年
2023年 | 5661篇 |
2022年 | 3352篇 |
2021年 | 8168篇 |
2020年 | 8811篇 |
2019年 | 7220篇 |
2018年 | 12820篇 |
2017年 | 11271篇 |
2016年 | 12716篇 |
2015年 | 13640篇 |
2014年 | 23046篇 |
2013年 | 26351篇 |
2012年 | 22997篇 |
2011年 | 23879篇 |
2010年 | 20258篇 |
2009年 | 22669篇 |
2008年 | 21942篇 |
2007年 | 21092篇 |
2006年 | 23296篇 |
2005年 | 20649篇 |
2004年 | 18945篇 |
2003年 | 16824篇 |
2002年 | 15947篇 |
2001年 | 5662篇 |
2000年 | 4393篇 |
1999年 | 5251篇 |
1998年 | 6457篇 |
1997年 | 5758篇 |
1996年 | 5299篇 |
1995年 | 5054篇 |
1994年 | 3568篇 |
1993年 | 3051篇 |
1992年 | 2560篇 |
1991年 | 2473篇 |
1990年 | 1984篇 |
1989年 | 2078篇 |
1988年 | 1928篇 |
1987年 | 1741篇 |
1986年 | 1784篇 |
1985年 | 1642篇 |
1984年 | 1731篇 |
1983年 | 1602篇 |
1982年 | 1851篇 |
1981年 | 1695篇 |
1980年 | 1494篇 |
1979年 | 1001篇 |
1978年 | 1057篇 |
1977年 | 1018篇 |
1976年 | 815篇 |
1975年 | 736篇 |
1974年 | 690篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
103.
104.
Yinong Young-Xu Julia Thornton Snider Robertus van Aalst Salaheddin M. Mahmud Edward W. Thommes Jason K.H. Lee David P. Greenberg Ayman Chit 《Vaccine》2019,37(11):1484-1490
Background
Observational studies of the relative effectiveness of influenza vaccines are essential for public health decision making. Their estimates, however, are subject to bias due to unmeasured confounders. Instrumental variable (IV) methods can control for observed and unobserved confounders.Methods
We used linked electronic medical record databases in the Veterans Health Administration (VHA) as well as Medicare administrative files to examine the relative vaccine effectiveness (rVE) of high-dose influenza vaccine (HD) versus standard-dose influenza vaccines (SD) in preventing hospitalizations among VHA-enrolled Veterans ≥65?years of age during 5 influenza seasons (2010–2011 through 2014–2015). Using multivariable IV Poisson regression modeling to address unmeasured confounding and bias, we analyzed the data by each season and through longitudinal analysis of all five seasons.Findings
We included 3,638,924 person–influenza seasons of observation where 158,636 (4%) were among HD vaccine recipients and 3,480,288 (96%) were among SD vaccine recipients. Of the 1,728,562 Veterans, 1,702,824 (98.5%) were male and 1,299,412 (75%) were non-Hispanic white. Based on the longitudinal analysis of all five seasons, the IV-adjusted rVE estimate of HD vs. SD was 10% (95% CI, 8–12%) against all-cause hospitalization; 18% (95% CI, 15–21%) against cardiorespiratory-associated hospitalization; and 14% (95% CI, 6–22%) against influenza/pneumonia-associated hospitalization. The findings by season were similar.Interpretation
Our analysis of VHA clinical data collected from approximately 1.7 million Veterans 65?years and older during five seasons demonstrates that high-dose influenza vaccine is more effective than standard-dose influenza vaccines in preventing influenza- or pneumonia-associated hospitalizations, cardiorespiratory hospitalizations, and all-cause hospitalizations. 相似文献105.
Gudrun Aspelund Elaa M Mahdi David H Rothstein Derek S Wakeman 《Journal of gastroenterology and hepatology》2019,34(6):966-974
Choledochal cysts (CDCs) and biliary atresia (BA) are rare pediatric hepatobiliary anomalies that require surgical intervention due to increased risk of malignancy and liver failure, respectively. The underlying disease and operative procedures place patients at risk for long‐term complications, which may continue to affect them into adulthood. Lack of a transitional care model in the health‐care system potentiates the challenges they will face following aging out of their pediatric providers' care. We sought to elucidate the long‐term complications and challenges patients with CDCs and BA face, review the current literature regarding transitioning care, and propose guidelines aiding adult providers in continued care and surveillance of these patients. A literature review was performed to assess short‐term and long‐term complications after surgery and the current standards for transitioning care in patients with a history of CDCs and BA. While transitional programs exist for patients with other gastrointestinal diseases, there are few that focus on CDCs or BA. Generally, authors encourage medical record transmission from pediatric to adult providers, ensuring accuracy of information and compliance with treatment plans. Patients with CDCs are at risk for developing biliary malignancies, cholangitis, and anastomotic strictures after resection. Patients with BA develop progressive liver failure, necessitating transplantation. There are no consensus guidelines regarding timing of follow up for these patients. Based on the best available evidence, we propose a schema for long‐term surveillance. 相似文献
106.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
107.
108.
Tormo Nuria Giménez Estela Martínez-Navarro María Albert Eliseo Navalpotro David Torres Ignacio Gimeno Concepción Navarro David 《European journal of clinical microbiology & infectious diseases》2022,41(4):657-662
European Journal of Clinical Microbiology & Infectious Diseases - We compared the performance of an in-house-developed flow cytometry assay for intracellular cytokine staining (FC-ICS) and a... 相似文献
109.
110.